Astraveus Secures Significant Funding for Innovative Growth
Astraveus SAS, known as the Benchtop Cell Factory company, has been awarded €7.1 million in non-dilutive funding by the French State. This funding is part of an initiative aimed at fostering innovation and enhancing business growth through the France 2030 investment program. The program focuses on ensuring that the next generation of technologies and business practices can flourish, contributing to improved economic competitiveness.
Pioneering the Future of Cell Therapy
The funding awarded to Astraveus is a result of their successful application to the "Première usine" project call, launched by Bpifrance. This competitive funding aims to support the establishment of manufacturing facilities for start-ups that are on the brink of achieving first industrialization successes. With this financial boost, Astraveus plans to build infrastructure for their innovative microfluidic consumables, essential for their goal of transforming cell therapy processing.
Advancing Manufacturing Infrastructure
The investment will enable Astraveus to progress with the development of the Lakhesys Benchtop Cell Factory™, a cutting-edge solution designed to enhance cell therapy production. This initiative is more than a leap in manufacturing; it's a commitment to creating therapies that are not only effective but also accessible to a wider patient base. This aligns with Astraveus' core mission: to revolutionize the way cell therapies are processed in order to offer cost-effective treatments globally.
CEO's Vision for the Future
Jérémie Laurent, the CEO of Astraveus, expressed enthusiasm regarding this funding. He stated, "This additional funding awarded by the French State through its France 2030 program reflects our innovative approach and dedication to transforming cell therapy manufacturing. We are eager to establish our industrialization infrastructure and drive our mission to make cell therapies more efficient and scalable." His insights highlight the company's commitment to improving therapy delivery, emphasizing the importance of accessibility and cost efficiency in healthcare.
About Astraveus
Astraveus is a biotech company dedicated to enhancing cell therapies through the development of advanced manufacturing processes. Established in 2016, it focuses on providing high-quality therapies at significantly reduced costs. The company's innovative Lakhesys Benchtop Cell Factory™ employs state-of-the-art microfluidic technology, optimizing bioprocessing from initial clinical trials to commercial production.
Expanding Horizons for Cellular Therapies
Located in a prestigious environment, Astraveus emerged at the Saint-Louis Hospital, a leading center for cell therapy research. The strong foundation established here empowers Astraveus in its mission to revolutionize the development and manufacturing of cell therapies. By making such innovative treatments accessible, the company aspires to foster healthier patient outcomes and contribute to global public health.
Frequently Asked Questions
What is the funding amount secured by Astraveus?
Astraveus has secured €7.1 million in non-dilutive funding from the French State.
What is the purpose of the funding?
The funding will support the establishment of manufacturing infrastructure for innovative microfluidic consumables, crucial for cell therapy processing.
What is the Lakhesys Benchtop Cell Factory™?
This factory is a solution developed by Astraveus that aims to enhance cell therapy manufacturing efficiencies, focusing on cost reduction and improved accessibility.
Who is the CEO of Astraveus?
The CEO of Astraveus is Jérémie Laurent, who has actively led the company since its inception.
When was Astraveus founded?
Astraveus was founded in 2016 at the Saint-Louis Hospital, a significant hub for cell therapy research.
